No Data
Information on individual stocks.
Material G <156A.T> significantly continued to rise. A self-stock acquisition limit of 400,000 shares (4.1% of the total outstanding stocks excluding treasury shares) and 260 million yen was established. The acquisition period is from April 18 to May 23. Progrit <9560.T> saw a significant rise, rebounding after six days. A self-stock acquisition limit of 350,000 shares (2.77% of the total outstanding stocks excluding treasury shares) and 300 million yen was established. The acquisition period is from April 18 to June 30. Genda <9166.T> saw a significant rise, rebounding after three days. The revenue for March.
JINSHD, Morinaga Milk, etc. (additional) Rating
Downgrade - Bearish Code Stock Name Brokerage Firm Previous Change After --------------------------------------------------------- <3479> TKP SMBC Nikko "1" "2" <4151> Kowa Kirin Daiwa "3" "4" <7272> Yamaha Motor Morgan Stanley "Overweight" "Equal Weight" Target Price Change Code Stock Name Brokerage Firm Previous Change After--------------------------------
Rating information (Target Price change) = JINS HD, Morinaga Milk, ETC.
◎ Mizuho Securities (three stages: Buy > Hold > underperform) JINS HD <3046.T> -- "Buy" → "Buy", 7,400 yen → 10,000 yen DCM <3050.T> -- "Buy" → "Buy", 1,700 yen → 1,600 yen 7&I HD <3382.T> -- "Buy" → "Buy", 2,950 yen → 2,900 yen Kansai Paint <4613.T> -- "Buy" → "Buy", 3,000 yen → 2,800 yen Idemitsu Kosan <5019.T> -- "Buy" → "Buy", 1,180 yen → 10.
Rohto has started domestic Phase II clinical trials for eye drops aimed at suppressing the progression of myopia.
On the 17th, Rohto <4527.T> announced that in collaboration with Tsubota Lab <4890.T>, it has begun a Phase 2 clinical trial in Japan for eye drops aimed at suppressing the progression of myopia (company development code "ROH-001") as a treatment drug in the Ophthalmology field. Up until now, efficacy and safety have been confirmed in the non-clinical phase and in the Phase 1 trials, hence, based on these trial results, this new trial will evaluate the efficacy and safety in myopia patients. The closing price on the 17th was,
List of conversion stocks [List of parabolic signal conversion stocks]
○ List of stocks undergoing a Buy conversion in the market Code Stock Name End Price SAR Main Board <1820> Nishimatsu Construction 4784 4180 <2207> Meito Sangyo 19571816 <2211> Fujiya 23862218 <2810> House Food Group 27572602 <2922> Natori 20001857 <3141> Welcia HD 22302043 <3834> Asahi Net 675622 <4527> Rohto Pharmaceutical 226720
Asset Value Investors Calls on Rohto Pharmaceutical to Focus on Core Business
